The company is currently a non-operational entity that holds a portfolio of equity investments and provides loans to other parties, while seeking new business opportunities in the pharmaceutical or trading sectors.
The company possesses no competitive advantage as it has no active business operations, no revenue from core services, and its assets consist of a fragmented portfolio of investments in other small-cap entities that have not yielded consistent returns.
Capital is primarily tied up in long-term loans and a diverse list of quoted and unquoted equity investments, many of which appear stagnant; the company has recently incurred significant losses from the sale of shares and regulatory penalties.
Over the next five years, the company's remaining capital base was systematically eroded by a combination of compounding regulatory penalties, unfavorable tax judgments, and the continued liquidation of its investment portfolio at fire-sale prices. The lack of a functional business model meant there was no operating income to offset these outflows, and the 'loans to others' were eventually written off as unrecoverable due to the absence of formal repayment terms. The entity effectively became a zombie shell, delisted from exchanges for persistent governance failures, leaving minority shareholders with a worthless stake in a pile of litigation and stagnant equity.
RichFakir rates Johnson Pharmacare Ltd's business quality as poor — 0/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
RichFakir's educational verdict on Johnson Pharmacare Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
View the full live analysis →